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of the study ﬁndings. The aim of this study was to determine whether
there existed signiﬁcant heterogeneity of treatment by center, coun-
try, or baseline risk factors for 5-year MACCE rates in the SYNTAX trial.
METHODS Patient level-data from the 5-year results of the SYNTAX
study were analyzed for the presence of geographical heterogeneity
(site/country) in the effect of treatment (CABG vs PCI) on 5-yr MACCE
rates. Fixed and random effects models examined potential in-
teractions, followed by generalized linear mixed models testing ef-
fects of clinical co-variates, such as diabetes, smoking rates, lesion
characteristics and procedural variations
RESULTS For site-site comparison for 5-yr MACCE rates, the pooled
odds ratio (OR) ¼ 0.58, and for country-country the OR¼0.59. By
simple homogeneity testing, site-stratum differences neared signiﬁ-
cance (73 analyzed sites, X2¼93.8, p¼0.051), whereas no country-
stratum differences (15 countries, X2¼25.7, p¼0.080) were observed.
For random effects models with site or country as the cluster variable,
intra-class correlation was minimal (ICC site ¼ 1.4%, ICC country ¼
0.6%), with no signiﬁcant heterogeneity of treatment effects
observed. Adjusted regression models for age (ICC ¼ 1.6%), male
gender (ICC¼1.2%), had no interaction effect on overall OR for MACCE
(OR¼0.59, 95% CI 0.48, 0.72, p<0.001). Wide variability in incident
baseline risk factors (smoking, diabetes, PVD) was observed - not ac-
counting for signiﬁcant site-site or geographic treatment interaction
in the adjusted models (ICC 1.0%-1.3%). Similarly, we observed wide
ranges across sites for, Left Main disease rates (range 21-57%), TVR
(range 8-31%), and PCI revascularization rates (range 8-31%), even
when pooled by country. Adjusting for Left Main versus 3-vessel
disease in the random effects models suggested PCI was protective of
MACCE (OR¼0.61, p<0.0001), with no difference between LM and 3-
vessel disease (p¼0.185), across site or country strata.
CONCLUSIONS As expected for this RCT, site-site and regional differ-
ences exist. Nonetheless, geographic variability in standard risk,
responsiveness to treatment, and vulnerability to adverse outcomes,
assessed by current models for heterogeneity analysis in clinical trials,
shows no signiﬁcant treatment effect. These ﬁndings highlight the
utility andgeneralizability of the 5-year outcomes of the SYNTAX study.
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BACKGROUND The incidence of peri-procedural myocardial infarc-
tion (PPMI) in patients treated with percutaneous coronary inter-
vention (PCI) varies largely between studies, and its clinical relevance
still remains a matter of debate. We sought to examine the incidence
of PPMI after bifurcation PCI using different deﬁnitions from the
TRYTON randomized trial.
METHODS The TRYTON trial randomized 704 patients with bifurcation
undergoing PCI to the Tryton side branch (SB) stentwithmain branch (MB)
DES vs. provisional SB treatment with MB DES. In the current study, we
reported and compared the incidence of PPMI after PCI, deﬁned according
three different deﬁnitions: per protocol (CK-MB 3 ULN), 3rd universal
(troponin rise of > 5  ULN), and SCAI (CK-MB rise of 10  ULN).RESULTS PPMI occurred in 81 out of 704 patients (11.5%) according to
the protocol deﬁnition, in 137 patients (19.5%), according to the
troponin-based third universal deﬁnition, and in 1.0% according to the
SCAI deﬁnition, with no signiﬁcant difference between the Tryton and
provisional group (Table). Access site (femoral vs radial; OR 0.60, 95%
CI 0.37-0.98), main vessel lesion length (OR 1.04, 95% CI 1.00-1.07),
and main vessel diameter stenosis (OR 1.02, 95% CI 1.00-1.05), the use
of devices other than angioplasty balloon (OR 3.77, 95% CI 1.02-13.86),
and the use of “non-study” stents were identiﬁed as independent
predictors of per-protocol PPMI. At 12-month follow-up, there were no
cardiac death in PPMI and two (5.9%) in no-PPMI patients (p¼0.61).
Patients who experienced protocol-deﬁned PPMI had signiﬁcantly
more target vessel revascularizations (11.1% vs. 5.1%; p¼0.02).Deﬁnition used Tryton Provisional Combined p-valueProtocol: CK-MB rise of
> 3x ULN13.6% (47/345) 10.1% (34/336) 11.5% (81/704) 0.193rd universal: troponin rise
of > 5  ULN
20.0% (71/355) 18.9% (66/349) 19.5% (137/704) 0.72SCAI: CK-MB rise of
10  ULN
1.4% (5/355) 0.6% (2/349) 1.0% (7/704) 0.26CONCLUSIONS The incidence of PPMI varies signiﬁcantly (by tenfold)
according to the deﬁnition used. However, PPMI, independent of the
PPMI deﬁnition, was not associated with an increase in cardiac mor-
tality at 1-year follow-up. These ﬁndings are important and may have
important implications when designing and selecting components of a
primary composite endpoint for PCI randomized trial.
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BACKGROUND Previous studies have shown that deferral of revas-
cularization in lesions with a fractional ﬂow reserve (FFR) > 0.80 is
safe and associated with signiﬁcantly lower incidence of major
adverse cardiovascular events (MACE) as compared to angiographic-
ally guided revascularization. DM patients have an accelerated
atherosclerosis progression compared to patients without DM.
Whether FFR-guided revascularization is also valid in DM patients is
unknown, therefore we performed a retrospective study in our center.
METHODS We assessed all consecutive DMpatients that underwent FFR-
guided revascularization between January 2011 and December 2013, and
followed them until May 2015. We further divided these patients into two
groups according to the presence or absence of 1 FFR-negative lesion (
0.80) remaining after index revascularization. DM was deﬁned as self-re-
ported by treatment with anti-diabetic medication or diet. The primary
endpoint was the incidence of MACE deﬁned as a composite of death,
myocardial infarction (MI), target lesion revascularization (TLR) or reho-
spitalization for acute coronary syndrome (ACS). Target lesionwas deﬁned
as the lesion(s) in which the FFR was performed. Logistic regression
analysis was performed to assess for predictors of MACE.
RESULTS Of the 224 DM patients that underwent FFR-guided revas-
cularization, 152(67.9%) had 1 FFR-negative lesion (Defer Group, DG)
while 72(32.1%) had only FFR-positive lesions, with resultant index
revascularization (Revascularization Group, RG). Overall, baseline
characteristics were well matched between groups, however there
were more females (37.5% vs 23.6%, p¼0.04) in the DG, while rates of
smoking (19.7% vs 34.7%, p¼0.02) and prior PCI (41.4% vs 56.9%,
p¼0.03) were higher in the RG. The MACE rate was 34.2% in the DG
and 26.4% in the RG, p¼ 0.24. The incidence of death was similar in
both groups 15.8% vs 15.3% p¼0.92. However a signiﬁcantly higher
rate of TLR (13.2% vs 4.2%, p¼0.038) and rehospitalization for ACS
(33.6% vs 19.4%, p¼0.03) was observed in the DG group. Similarly a
numerically higher incidence of MI was also observed but did not
reach signiﬁcance (7.2% vs 4.2%, p¼0.56). Logistic regression analysis
showed that increasing age, elevated HbA1c and renal insufﬁciency
